Heat Shock Proteins Come of Age: Primitive Functions Acquire New Roles in an Adaptive World

Srivastava, Pramod K.; Ménoret, Antoine; Basu, Sreyashi; Binder, Robert J.; McQuade, Kristi L.

doi:10.1016/s1074-7613(00)80570-1

Cited by 516 publications

(321 citation statements)

References 76 publications

Supporting

Mentioning

312

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that hsp90 purified from autologous tumours has a protective effect in mouse (Graner et al, 2000;Ullrich et al, 1986). It is now believed that such a protective effect of hsp90 is mainly due to the tumour-derived antigenic peptides that bind to it (Ishii et al, 1999;Srivastava et al, 1998;Wells and Malkovsky, 2000). In our study, since the prokaryotic expression library and purified hsp90 from HeLa cells are unlikely to harbour such antigenic peptides, it seems that the immunoreactivities that we observed are hsp90 specific.…”

Section: Discussionmentioning

confidence: 99%

Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library

et al. 2002

View full text Add to dashboard Cite

Serological screening of recombinant cDNA expression libraries has been widely used for the identification of tumour antigens in various cancer types. Identification of tumour antigens in ovarian cancer may facilitate the development of vaccine-based therapies and of disease biomarkers. The purpose of our investigation is to identify tumour antigens in ovarian cancer by using the serological analysis of recombinant cDNA expression libraries method. A recombinant ovarian carcinoma cDNA expression library was screened with ascites fluid, pooled from five ovarian cancer patients. Twelve tumour antigens encoded by known genes were isolated, including ribosomal protein S18, heat shock protein 90, JK-recombination signal binding protein, ribonucleoprotein H1, RAN binding protein 7, TG-interacting factor, eukaryotic translation initiation factor p40 subunit, human amyloid precursor protein-binding protein 1, ribosomal protein L8, CDC23, IQ motif containing GTPase activating protein 1, and ribosomal protein L3. Heat shock protein 90 was chosen for further investigation. The prevalence of hsp90 autoantibodies in ovarian cancer was determined with immunoassay. Sera from 22 normal females, 32 from ovarian cancer (22 stage III/IV, 10 stage I/II), 37 colorectal cancer, 13 breast cancer, 10 lung cancer, 20 benign gynaecologic diseases, and 10 benign breast lesions were screened. Seven (32%) stage III/IV ovarian cancer, 1 (10%) stage I/II ovarian cancer, 1 (3%) colorectal cancer, 1 (8%) breast cancer, and 1 (5%) benign gynaecologic disease sera were found to contain hsp90 autoantibodies. These data support the view that hsp90 autoantibodies are frequently found in late stage ovarian cancer. Hsp90 may, therefore, represent a novel biomarker for ovarian cancer and a candidate ovarian cancer vaccine target.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library

et al. 2002

View full text Add to dashboard Cite

show abstract

“…On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90 and glucose-regulated protein 96 (gp96), in immune reactions. 14,15 HSP-mediated antitumor immunity has been reported in human melanoma and HSP-peptide complexes purified from human melanoma cells induced a vaccine-like effect. 16 With regard to the mechanism of antitumor immunity induced by hyperthermia using MCLs, we previously demonstrated that HSP70 expression during hyperthermia-induced antitumor immunity against the T-9 rat glioma 17,18 ; our hyperthermia system leads to vaccination with HSP70-peptide complexes via necrotic tumor cell death in vivo, thus resulting in antitumor immunity.…”

mentioning

confidence: 99%

Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles

Tanaka

Ito

Kobayashi

et al. 2005

Intl Journal of Cancer

114

View full text Add to dashboard Cite

Dendritic cells (DCs) are potent antigen-presenting cells that play a pivotal role in regulating immune responses in cancer and have recently been shown to be activated by heat shock proteins (HSPs). We previously reported that HSP70 expression after hyperthermia induces antitumor immunity. Our hyperthermia system using magnetite cationic liposomes (MCLs) induced necrotic cell death that was correlated with HSP70 release. In the present study, we investigated the therapeutic effects of DC therapy combined with MCL-induced hyperthermia on mouse melanoma. In an in vitro study, when immature DCs were pulsed with mouse B16 melanoma cells heated at 43°C, major histocompatibility complex (MHC) class I/II, costimulatory molecules CD80/ CD86 and CCR7 in the DCs were upregulated, thus resulting in DC maturation. C57BL/6 mice bearing a melanoma nodule were subjected to combination therapy using hyperthermia and DC immunotherapy in vivo by means of tumor-specific hyperthermia using MCLs and directly injected immature DCs. Mice were divided into 4 groups: group I (control), group II (hyperthermia), group III (DC therapy) and group IV (hyperthermia 1 DC therapy). Complete regression of tumors was observed in 60% of mice in group IV, while no tumor regression was seen among mice in the other groups. Increased cytotoxic T lymphocyte (CTL) and natural killer (NK) activity was observed on in vitro cytotoxicity assay using splenocytes in the cured mice treated with combination therapy, and the cured mice rejected a second challenge of B16 melanoma cells. This study has important implications for the application of MCL-induced hyperthermia plus DC therapy in patients with advanced malignancies as a novel cancer therapy. ' 2005 Wiley-Liss, Inc.Key words: hyperthermia; dendritic cell; antitumor immunity; magnetite cationic liposome; melanoma Hyperthermia has been used for many years to treat a wide variety of tumors in both experimental animals and patients. 1 The most commonly used heating method in clinical settings is capacitive heating using a radiofrequency (RF) electric field. 2 However, the problem with capacitive heating using an RF electric field is the difficulty in heating only the local tumor region at the intended temperature without damaging normal tissue, because electromagnetic energy is conducted from outside the body by penetrating normal tissue and is imperfectly transduced to heat; the heating characteristics are influenced by various factors, such as tumor size, position of electrodes, and adhesion of electrodes at uneven sites. Magnetic nanoparticles have thus been applied to hyperthermia in an attempt to overcome these disadvantages. 3,4 Magnetic nanoparticles act as a transducer to change electromagnetic energy to heat; such nanoparticles generate heat in an alternating magnetic field (AMF) due to hysteresis loss. As a result, only tissue accumulating magnetite nanoparticles is heated. 5 We subsequently developed magnetite cationic liposomes (MCLs) for use as an intracellular heating mediator. 6 MCLs were dev...

show abstract

“…On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90, and glucose-regulated protein 96 (gp96), in immune reactions. 18,19 A possible mechanism by which HSPs influence tumor cell immunogenicity is associated with the processing and presentation of endogenous tumor antigens directly to tumor-specific T cells. 20 Srivastava and coworkers [21][22][23] proposed the following relay line model for tumor antigenic peptide transfer during antigen processing and presentation by HSPs.…”

mentioning

confidence: 99%

Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles

et al. 2003

View full text Add to dashboard Cite

Heat shock proteins (HSPs) are recognized as significant participants in immune reactions. We previously reported that expression of HSP70 in response to hyperthermia, produced using our original magnetite cationic liposomes (MCLs), induces antitumor immunity. In the present study, we examine whether the antitumor immunity induced by hyperthermia is enhanced by hsp70 gene transfer. A human hsp70 gene mediated by cationic liposomes was injected into a B16 melanoma nodule in C57BL/6 mice in situ. At 24 hours after the injection of the hsp70 gene, MCLs were injected into melanoma nodules in C57BL/6 mice, which were subjected to an alternating magnetic field for 30 minutes. The temperature at the tumor reached 431C and was maintained by controlling the magnetic field intensity. The combined treatment strongly arrested tumor growth over a 30-day period, and complete regression of tumors was observed in 30% (3/10) of mice. Systemic antitumor immunity was induced in the cured mice. This study demonstrates that this novel therapeutic strategy combining the use of hsp70 gene therapy and hyperthermia using MCLs may be applicable to patients with advanced malignancies. Cancer Gene Therapy (2003) 10, 918-925. doi:10.1038/sj.cgt.7700648Keywords: heat shock proteins; hyperthermia; magnetite; cancer immunotherapy H yperthermia is a promising approach for cancer therapy. 1,2 However, the inevitable technical problem with hyperthermia is the difficulty in heating only the local tumor region to the intended temperature without damaging the surrounding normal tissue. Magnetic nanoparticles have been used for hyperthermia treatment in an attempt to overcome these disadvantages. 3,4 Magnetic nanoparticles generate heat in an alternating magnetic field (AMF) due to hysteresis loss. 5 We have developed magnetite cationic liposomes (MCLs) for intracellular hyperthermia. 6,7 The hyperthermic effect of MCLs was examined in an in vivo study, and complete tumor regression was observed. 8 Since some researchers have reported that heat treatment itself can enhance the immunogenicity of cancer cells, 9-12 we previously investigated hyperthermia-induced antitumor immunity in T-9 rat glioma cells in vivo. 13 This induced immunity continued for an extended period of time, and the rats treated with hyperthermia completely rejected T-9 cells as a metastasis model. Moreover, we investigated the mechanisms of antitumor immunity induced by intracellular hyperthermia with regard to the role of heat shock proteins (HSPs). 14,15 HSPs are a highly conserved group of intracellular proteins whose synthesis is increased by a large variety of stressors including heat shock. 16 As expression of HSP70 protects cells from heat-induced apoptosis, 17 HSP70 expression is considered a complicating factor in hyperthermia. On the other hand, recent reports have shown the importance of HSPs, such as HSP70, HSP90, and glucose-regulated protein 96 (gp96), in immune reactions. 18,19 A possible mechanism by which HSPs influence tumor cell immunogenicity is associated with...

show abstract

Heat Shock Proteins Come of Age: Primitive Functions Acquire New Roles in an Adaptive World

Abstract: Cross-reactive protection was observed in some studies but, with notable exceptions (e.g., Donawho and Kripke, 1990;Frey and Cestari, 1995), such immunity was substantially weaker than the individually specific immunity (Coggin and Anderson, 1974).

Cited by 516 publications

References 76 publications

Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library

Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library

Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles

Heat shock protein 70 gene therapy combined with hyperthermia using magnetic nanoparticles

Contact Info

Product

Resources

About